** Healthcare technology co Resmed's Australia-listed shares RMD.AX fall 2.7% to A$39.105, on track for worst session since Oct. 29, 2024 - if current losses hold
** Stock tracks a sell-off in broader market .AXJO, which is down 1.7% .AX
** Meanwhile, Macquarie hikes PT to A$45.10 from A$41.10, signalling a 9.7% upside potential
** PT hike reflects 1% increase in earnings forecasts for FY25 and 26, driven by foreign exchange and buyback assumptions adjustments, among others
** Nine of 11 analysts rate the stock "buy" or higher, and two "hold"; their median PT is A$43.80 – LSEG data
** Stock rose 44.5% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.